Giuseppe Curigliano: Excited that the DESTINY-06 trial was presented at ASCO2024

Giuseppe Curigliano shared on LinkedIn:

“Excited to share that the DESTINY-06 trial was presented at ASCO2024 and received fantastic feedback from our outstanding audience!

A huge thank you to everyone who attended and supported our work in advancing cancer treatment.

Together, we’re making strides in oncology!”

Source: Giuseppe Curigliano/LinkedIn

Giuseppe Curigliano, MD, PhD, is the Director of  the Early Drug Development Division and co-chairs the Experimental Therapeutics Program at the European Institute of Oncology.

He is a member of the Department of Oncology and Hemato-Oncology’s steering committee at the University of Milan and serves on the Italian National Health Council, advising the Ministry of Health on cancer policy issues.